Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
Company Details
- Employees
- 34
- Address
- Västra Trädgårdsgatan 15, Stockholm,stockholm County 11153,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- immunicum.se
- HQ
- Stockholm, Stockholm County
Mendus Ab Questions
Mendus Ab's website is immunicum.se
Mendus Ab's LinkedIn profile is https://se.linkedin.com/company/mendus
Mendus Ab has
34 employees.
View email and phone details for 34
employees at Mendus Ab.
Mendus Ab's industry is
Biotechnology Research
Mendus Ab's top competitors are
Northx Biologics,
Eukarÿs,
Anocca,
Atmp Sweden,
Elicera Therapeutics Ab,
Bioarctic,
Alzinova Ab,
Oncopeptides Ab (Publ),
Kancera,
Cereno Scientific.
Mendus Ab's categories are Biotechnology Research
